Rhinosinusitis, Nasal Polyps, and Asthma – What to Do? (AAN)

Many clinicians struggle to recognize the interconnected pathophysiology of chronic rhinosinusitis, nasal polyps, asthma, and unified airway inflammation. Diagnostic distinctions such as differing inflammatory endotypes and the significance of eosinophilia are often overlooked. Clinicians may lack familiarity with emerging data on biologics, aspirin desensitization, and the impact of endoscopic sinus surgery on asthma outcomes. These gaps lead to underdiagnosis, delayed treatment escalation, and inconsistent management. This activity will address mechanisms, evidence-based therapeutic options, and practical approaches to optimize outcomes for patients with CRS, nasal polyps, and comorbid asthma.

This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network (AAN).

Explore other archived clinical webinars here.

Session recorded on December 4, 2025
Speaker: Andrew White, MD, FACAAI

Price: FREE for members and non-members

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Primary Care Providers
Allied Health Professionals

Learning Objectives

Upon completion of this activity learners should be able to:

1.    Describe the mechanisms and clinical significance of unified airway inflammation in CRS, nasal polyps, and asthma.
2.    Differentiate inflammatory endotypes of CRSwNP and identify features such as eosinophilia, AERD, and comorbid asthma.
3.    Apply individualized treatment strategies that integrate sinus and asthma management to improve overall patient outcomes.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. 

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be Ineligible Companies. Examples of ineligible companies include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
12/08/2025
Course expires: 
12/31/2026
Rating: 
0

All identified relevant financial relationships with ineligible companies have been mitigated.

Speaker:
Andrew White, MD, FACAAI
Advisor: Sanofi/Regeneron, GSK, Blueprint Medicines, AstraZeneca
Speaker: Sanofi/Regeneron, Optinose, Genentech, GSK, Blueprint Medicines, AstraZeneca
Researcher: Sanofi/Regeneron, Telios, Cogent

Moderator:
Ruthie Marker, AAN Staff
No relevant financial relationships with ineligible companies to disclose

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.